Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

4.2%

1 terminated out of 24 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed with results

Key Signals

1 with results86% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (8)
Early P 1 (1)
P 1 (4)
P 2 (2)
P 3 (1)
P 4 (1)

Trial Status

Recruiting10
Completed6
Active Not Recruiting3
Not Yet Recruiting1
Unknown1
Terminated1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT04189783Phase 2Active Not RecruitingPrimary

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

NCT06753136Not ApplicableRecruiting

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

NCT04031677Phase 3RecruitingPrimary

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT06025747Phase 1RecruitingPrimary

Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma

NCT01659203Phase 1RecruitingPrimary

Proton or Photon RT for Retroperitoneal Sarcomas

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT07396116Not ApplicableNot Yet Recruiting

Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)

NCT06943612Recruiting

Colorectal Resections in Patients With Retroperitoneal Sarcoma

NCT05224934Not ApplicableRecruiting

Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)

NCT04224948Not ApplicableCompletedPrimary

The PET- Retroperitoneal Sarcoma Study

NCT06327477Phase 1RecruitingPrimary

Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma

NCT06812052Phase 1RecruitingPrimary

Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery

NCT06741423Active Not RecruitingPrimary

Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics

NCT05631379CompletedPrimary

Influence of Nutritional Status on Oncologic and Operative Outcome in Patients Operated for Retroperitoneal Sarcoma

NCT06612671Active Not RecruitingPrimary

Treatment Outcomes of Retroperitoneal Sarcoma

NCT02384473Early Phase 1Completed

Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma

NCT03792867Not ApplicableUnknownPrimary

Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma

NCT05844813Phase 4Enrolling By InvitationPrimary

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma

NCT05302570Phase 2WithdrawnPrimary

Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS

NCT04225494Completed

Perioperative Residual Adrenal Function After Extended Resection for Retroperitoneal Soft Tissue Sarcomas

Scroll to load more

Research Network

Activity Timeline